Concord Biotech Faces Challenges Amid Declining Sales and Investor Sentiment Shift

Aug 19 2025 08:50 AM IST
share
Share Via
Concord Biotech has recently experienced a change in its evaluation score, indicating a shift in technical trends. The company reported a net sales figure of Rs 203.99 crore and a profit after tax of Rs 44.06 crore, reflecting significant challenges. Institutional investor participation has also declined, suggesting cautious sentiment.
Concord Biotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation score. This revision reflects a shift in technical trends, moving from a bearish outlook to a mildly bearish stance.

Key financial metrics indicate a challenging landscape for the company. In the latest quarter, Concord Biotech reported a net sales figure of Rs 203.99 crore, marking a significant low. The profit after tax (PAT) for the quarter stood at Rs 44.06 crore, which represents a notable decline of 52.6% compared to the previous four-quarter average. Additionally, the operating profit has shown a modest annual growth rate of 19.91% over the past five years, raising concerns about long-term growth potential.

The stock's current price is Rs 1,633.75, slightly above its previous close of Rs 1,629.60. Over the past year, the stock has generated a return of 0.09%, while profits have increased by 13.7%. However, the company's price-to-book value ratio of 10.7 suggests a relatively expensive valuation compared to its peers.

Institutional investor participation has also seen a decline, with a decrease of 0.54% in their stake over the previous quarter, now holding 17.97% of the company. This trend may reflect a cautious sentiment among larger investors regarding Concord Biotech's future prospects.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News